为您找到相关结果约500个

你是不是要搜索 期刊中国PD-1抑制剂信迪利单抗治疗cHL关键研究荣登《柳叶刀血液 点击跳转

F-18-FDG-PET/CT for treatment response assessment in classical Hodgkin Lymphoma (cHL) under immunomodulatoryPD-1 blocked (nivolumab) therapy

A PHASE II STUDY OF THE ANTI-PROGRAMMED CELL DEATH-1 (PD-1) ANTIBODY PENPULIMAB IN PATIENTS WITH RELAPSEDOR REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL)

A phase I/II study of the anti-programmed cell death-1 (PD-1) antibody AK105 in patients with relapsedor refractory classic Hodgkin lymphoma (cHL).

Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1)

Exact effective interactions and 1/4-BPS dyons in heterotic CHL orbifolds

Dualities in CHL-models

Favezelimab (anti-LAG-3) plus pembrolizumab in patients with anti-PD-1-naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)

anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study.

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis

PD-1/PD-L1 in disease

Improved survival in cHL with novel

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling

Revving up the immune engine in cHL

为您找到相关结果约500个

共500条页码: 1/34页15条/页